---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-027247"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-09-12T23:59:59+00:00"
generated_at: "2026-05-17T06:43:42.804668+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma showcases CDI-988 at calicivirus conference, notes FDA clearance for Phase 1b challenge study

## Summary
- President/co-CEO Sam Lee presented CDI-988 Phase 1 data at 9th International Calicivirus Conference (Sept 7–11) in Banff.
- CDI-988 is a first oral antiviral candidate for norovirus, with broad-spectrum activity against GII.4 and GII.17.
- Phase 1 showed favorable safety and tolerability, with no serious adverse events.
- FDA cleared a Phase 1b human challenge study for norovirus prophylaxis/treatment; expected start before end of 2025.
- CDI-988 targets a conserved region in 3CL viral proteases, designed with Cocrystal's proprietary structure-based platform.

## SEC filing metadata
- accession: 0001641172-25-027247
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225027247/0001641172-25-027247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225027247/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-027247
- JSON: https://secwatch.observer/filing/0001641172-25-027247.json
- Plain text: https://secwatch.observer/filing/0001641172-25-027247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.